

Marieke Krol

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5340469/publications.pdf>

Version: 2024-02-01

29
papers

1,384
citations

471509

17
h-index

501196

28
g-index

31
all docs

31
docs citations

31
times ranked

2105
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | A Delphi panel on treatment of high disease activity relapsing remitting multiple sclerosis in the Netherlands. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 93-100. | 1.4 | 0 |
| 2 | Concerns, quality of life, access to care and productivity of the general population during the first 8 weeks of the coronavirus lockdown in Belgium and the Netherlands. <i>BMC Health Services Research</i> , 2021, 21, 227. | 2.2 | 44 |
| 3 | Measurement Instruments of Productivity Loss of Paid and Unpaid Work: A Systematic Review and Assessment of Suitability for Health Economic Evaluations From a Societal Perspective. <i>Value in Health</i> , 2021, 24, 1686-1699. | 0.3 | 21 |
| 4 | Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 857-873. | 2.1 | 11 |
| 5 | Health state utilities for infertility and subfertility. <i>Reproductive Health</i> , 2019, 16, 47. | 3.1 | 6 |
| 6 | New findings from the time trade-off for income approach to elicit willingness to pay for a quality adjusted life year. <i>European Journal of Health Economics</i> , 2018, 19, 277-291. | 2.8 | 9 |
| 7 | Measurement and evaluation of quality of life and well-being in individuals having or having had fertility problems: a systematic review. <i>European Journal of Contraception and Reproductive Health Care</i> , 2018, 23, 441-450. | 1.5 | 10 |
| 8 | Healthcare utilization and costs of multiple sclerosis patients in the Netherlands: a healthcare claims database study. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 453-462. | 1.4 | 7 |
| 9 | Patient adherence to subcutaneous IFN beta-1a injections using the RebiSmart [®] injection device: a retrospective real-world study among Dutch and German patients with multiple sclerosis. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 1189-1196. | 1.8 | 12 |
| 10 | Altruistic Preferences in Time Tradeoff. <i>Medical Decision Making</i> , 2016, 36, 187-198. | 2.4 | 11 |
| 11 | A noticeable difference? Productivity costs related to paid and unpaid work in economic evaluations on expensive drugs. <i>European Journal of Health Economics</i> , 2016, 17, 391-402. | 2.8 | 39 |
| 12 | Exploring a new method for deriving the monetary value of a QALY. <i>European Journal of Health Economics</i> , 2016, 17, 801-809. | 2.8 | 12 |
| 13 | The iMTA Productivity Cost Questionnaire. <i>Value in Health</i> , 2015, 18, 753-758. | 0.3 | 298 |
| 14 | Unpaid work in health economic evaluations. <i>Social Science and Medicine</i> , 2015, 144, 127-137. | 3.8 | 42 |
| 15 | Does Including Informal Care in Economic Evaluations Matter? A Systematic Review of Inclusion and Impact of Informal Care in Cost-Effectiveness Studies. <i>Pharmacoeconomics</i> , 2015, 33, 123-135. | 3.3 | 112 |
| 16 | Predicting productivity based on EQ-5D: an explorative study. <i>European Journal of Health Economics</i> , 2014, 15, 465-475. | 2.8 | 19 |
| 17 | How to Estimate Productivity Costs in Economic Evaluations. <i>Pharmacoeconomics</i> , 2014, 32, 335-344. | 3.3 | 144 |
| 18 | Productivity Costs in Economic Evaluations: Past, Present, Future. <i>Pharmacoeconomics</i> , 2013, 31, 537-549. | 3.3 | 162 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | The Impact of Patientsâ€™ Subjective Life Expectancy on Time Tradeoff Valuations. Medical Decision Making, 2013, 33, 261-270. | 2.4 | 26 |
| 20 | Economic evaluations in European reimbursement submission guidelines: current status and comparisons. Expert Review of Pharmacoeconomics and Outcomes Research, 2013, 13, 579-595. | 1.4 | 19 |
| 21 | Productivity cost calculations in health economic evaluations: Correcting for compensation mechanisms and multiplier effects. Social Science and Medicine, 2012, 75, 1981-1988. | 3.8 | 44 |
| 22 | Does the EQ-5D Reflect Lost Earnings?. Pharmacoeconomics, 2012, 30, 47-61. | 3.3 | 25 |
| 23 | Do Productivity Costs Matter?. Pharmacoeconomics, 2011, 29, 601-619. | 3.3 | 102 |
| 24 | In or Out? Income Losses in Health State Valuations: A Review. Value in Health, 2010, 13, 298-305. | 0.3 | 41 |
| 25 | Breaking the Silence: Exploring the Potential Effects of Explicit Instructions on Incorporating Income and Leisure in TTO Exercises. Value in Health, 2009, 12, 172-180. | 0.3 | 14 |
| 26 | Costs, quality of life, treatment satisfaction and compliance in patients with β^2 -thalassemia major undergoing iron chelation therapy: the ITHACA study. Current Medical Research and Opinion, 2008, 24, 1905-1917. | 1.9 | 101 |
| 27 | A systematic review of economic analyses of pharmaceutical therapies for advanced colorectal cancer. Expert Opinion on Pharmacotherapy, 2007, 8, 1313-1328. | 1.8 | 19 |
| 28 | Productivity Costs in Health-State Valuations. Pharmacoeconomics, 2006, 24, 401-414. | 3.3 | 28 |
| 29 | Direct and Indirect Cost of Beta Thalassemia Major: Results from the ITHACA Study.. Blood, 2006, 108, 3343-3343. | 1.4 | 2 |